Litigation Capital Management Limited Overview
Litigation Capital Management is an Australian-domiciled, AIM-listed disputes financier. For over two decades it funded commercial litigation, class actions, insolvency claims and international arbitration in Australia, the UK and Asia. From 2020 it moved towards an asset-management model, raising US$441m across two private funds, and pitched itself as a premium, actively managed alternative to lawyer-led funders. That model has now failed. Across FY2025 and FY2026 a cluster of large, concentrated case losses wiped out A$238.6m of after-tax earnings. A performance-fee clawback provision and uninsured adverse costs added to the damage. Net assets swung from A$188.9m at June 2024 to net liabilities of A$53.6m at June 2026. A strategic review produced no transaction. The company is now a lender-controlled run-off vehicle: a 37-case portfolio is being worked out for the benefit of Northleaf, whose amended facility must be repaid in full, at a minimum of twice drawn principal, before shareholders can receive anything.
Company's own description
In its FY2026 results, LCM describes itself as a disputes financing business that has funded claimants internationally through direct balance-sheet investments and third-party funds under management. Following the strategic review, it states that the existing portfolio will be managed to conclusion, no new investments will be made, and realised cash will be applied to repaying the debt facility.
Until FY2025 the company's standard description was "an alternative asset manager specialising in disputes financing solutions internationally" with two business models (balance sheet and third-party fund management) and three strategies (single-case funding, portfolio funding and acquisitions of claims).
Business model (historical, as it operated to FY2025)
Direct investments (balance sheet): LCM paid the legal costs, expert fees and often adverse-cost insurance premiums of a claimant. In return it received a share of the award or settlement, or a multiple of deployed capital, plus reimbursement of invested capital. If the case lost, the investment went to zero, and adverse-cost exposure was covered by after-the-event (ATE) insurance where purchased.
Fund management: From 2020, new cases were typically co-funded 25% from LCM's balance sheet and 75% from third-party funds (Fund I and Fund II). LCM earned performance fees on fund realisations above hurdles. Fund I paid LCM US$28.9m of performance fees on early realisations, and these are now subject to a clawback provision.
Risk management services: LCM described "litigation finance and risk management" as its principal activity, including portfolio solutions for corporates and insolvency practitioners.
Revenue model
| Income line (LCM-only basis) | Nature |
|---|---|
| Net realised gains/losses on concluded investments | Proceeds on LCM capital, less capital invested, on cases that conclude |
| Performance fees on third-party capital | Carried interest from Funds I and II (negative in FY26 owing to a A$27.0m reversal and clawback) |
| Net fair value movement | Mark-to-model changes on ongoing cases (IFRS 9, Level 3, DCF with milestone risk adjustments) |
| Litigation service revenue / expense | Legacy cases held at contract cost under AASB 15 |
| Other income | Fund expense reimbursements |
Income is almost entirely investment-return driven. There are no product, subscription or licensing revenues.
Value chain position, customers and end-markets
LCM sits between claimants and their lawyers on one side and capital providers (its own shareholders, fund LPs and its lender) on the other. Its customers were:
-
corporate claimants in commercial disputes;
-
investors bringing investment-treaty claims against sovereign states (for example Green-X Metals against Poland, and a claim against Tanzania);
-
class action group members in Australia and the UK;
-
insolvency practitioners and liquidators;
-
competition (antitrust) claimants;
-
IP owners, including a US IP case.
Independent characterisation
LCM was a sub-scale, concentrated single-case funder that layered a fund-management model on top of a small balance sheet and then added senior secured leverage. The company itself says three cases made up most of its balance-sheet invested capital at June 2025, and that by FY2026 losses were compounded by concentration in a small number of large cases. The asset-management pivot raised fee-earning capital but did not diversify the balance sheet enough to absorb binary losses. The CEO conceded in FY2025 that the investment process had drifted towards a lawyer-led approach as he shifted his focus to fundraising. In its current form LCM is a liquidating portfolio whose equity is deeply subordinated to a payment-in-kind (PIK), limited-recourse lender claim.
Strategy
Strategic arc
| Period | Stated strategy themes |
|---|---|
| FY2020–FY2024 | Transition to asset management (25% balance sheet / 75% funds); grow funds under management; London and Asia-Pacific origination; fair value accounting to show embedded value; capital returns; Fund III; staged US entry |
| FY2025 | "Refocused investment strategy" and return to hands-on active case management; decisive exits from underperformers; sizing discipline to manage concentration; independent quantitative scrutiny of expert evidence; cost base halved; strategic review benchmarked against "lean run-off" |
| FY2026 (current) | Orderly run-off under a Northleaf-approved business plan; no new investments (not contemplated and not permitted under the Northleaf agreement); cash applied first to the facility; further cost reductions |
Initiatives in the last 24 months
| Initiative | Date | Status / outcome |
|---|---|---|
| Fund III fundraise | Marketing from late 2024 | First close expected May 2025; suspended after Dubai media reports; abandoned |
| US market entry | Announced September 2024 | Not executed |
| Fair value model recalibration (lower profit assumptions for group claims, longer durations, slower risk-adjusted recognition; appeal losses held at 50–60% of cost) | FY2025 | Implemented; annual review instituted |
| Cost reduction programme | From H2 FY2025 | Operating expenses A$19.0m (FY24) to A$18.0m (FY25) to A$11.0m (FY26); further cuts promised in run-off |
| Portfolio re-underwriting and selective exits (for example Gladstone) | FY2025–FY2026 | Ongoing cases reduced from 53 to 37 |
| Strategic review (Luminis) | 15 Sep 2025 – 30 Sep 2026 | Concluded with no transaction |
| Recovery actions against Gladstone solicitors (costs assessment; negligence and breach-of-contract claim) | From September 2025 | Outcome not disclosed |
| Legal options against UAE authorities over the leaked Dubai probe | Announced October 2025 | Under review |
| ESG / sustainability commitments | — | — |
Guidance / medium-term targets
LCM gives no numerical guidance. Its implicit objective is to realise the portfolio and repay Northleaf. The first financial covenant test under the amended facility falls on 31 December 2027.
Products & Services
LCM sells no physical products. The catalogue below covers its financing strategies, case types and fund vehicles. All are now closed to new business under run-off.
Investment strategies
| Offering | Description | Target customer | Launch / status | Pricing model |
|---|---|---|---|---|
| Single-case funding | Finances one dispute: legal fees, experts, sometimes ATE premiums | Corporate claimants, treaty claimants, class action groups | Since inception (1998 predecessor); the largest strategy | Percentage of proceeds or multiple of capital deployed, plus return of capital |
| Portfolio funding | Finances a bundle of disputes for a law firm, insolvency practitioner or corporate, with cross-collateralisation | Corporates (main focus), law firms, insolvency practitioners | Developed over the 2010s–2020s; closed under run-off | Portfolio-level return; terms not publicly disclosed |
| Acquisition of claims | Buys or takes assignment of smaller (typically insolvency) causes of action and pursues recovery as principal | Liquidators and administrators | "Early stages of evolution" per FY25 and H1 FY26 reports; closed under run-off | Principal recovery |
| Disputes risk management | Risk management and financing products for disputes, including adverse-cost cover structuring | Claimants and corporates | Described as a principal activity; no standalone revenue disclosed | — |
Case types funded (from FY2025 concluded-case table and RNS)
| Case type | Named / disclosed examples | Notes |
|---|---|---|
| Investment treaty arbitration | Green-X Metals v Poland (ECT and Australia–Poland BIT awards); claim against Tanzania | FY25 treaty wins returned 9.0x and 6.8x MOIC. Green-X v Poland contributed A$26.1m of net realised gains and Tanzania A$12.0m |
| Commercial arbitration | UK commercial arbitration (A$5.3m, lost, appeal); commercial arbitration lost 1 April 2025 (A$2.6m) | Mixed outcomes |
| Commercial litigation (UK) | UK commercial claim with A$20.6m of LCM capital, co-funded with Fund I, lost at High Court 1 October 2025 | Held at £26.5m (A$55.3m) fair value at 30 June 2025 per press reports |
| Commercial litigation (Australia) | Trademark dispute won in the High Court of Australia (A$3.3m invested, March 2026); A$1.4m claim lost 17 March 2026 | Quantification of damages pending in the trademark matter |
| Class actions (Australia) | Gladstone Ports (terminated, A$30.8m written off); Queensland Electricity (lost, about A$32.4m total adverse costs, A$12.9m uninsured to LCM); Quintis (lost February 2025, appeal) | Main source of losses |
| Class actions (UK) | UK class action loss (A$1.0m) in FY25 | — |
| Competition | Two FY25 losses (A$1.9m and A$1.7m); permission to appeal refused 3 July 2026 (A$1.5m write-off) | UK CAT-type claims |
| Insolvency | Australian insolvency wins (1.9x and 4.5x MOIC in FY25); US insolvency win (1.5x); Australian insolvency claim lost 8 October 2026 (A$2.9m) | Historically high hit rate, small tickets |
| Intellectual property | US IP case lost in FY25 (A$4.5m) | Only disclosed US exposure besides insolvency |
Fund vehicles
| Fund | Size (external capital) | Status | Performance disclosed |
|---|---|---|---|
| Fund I: LCM Global Alternative Returns Fund | US$150m | Fully committed, 85% deployed (June 2025); 23 investments net of 3 terminations | 12 concluded (9 wins, 3 losses): gross proceeds US$121.3m on LP capital of US$54.9m; LP net MOIC 1.7x, net IRR 30.4% (to June 2025). LCM received US$28.9m in performance fees; A$20.4m clawback provision raised in FY26 |
| Fund II: LCM Global Alternative Returns Fund II | US$291m (final close 2023) | Closed to new business at about 65% committed; about US$50m deployed (June 2025); 37 cases net of 13 terminations | 5 concluded (2 wins, 3 losses), aggregate MOIC 0.2x |
| Fund III | — | Marketing began late 2024; first close expected early May 2025 but suspended after the Dubai media reports; abandoned in run-off | — |
Financial Narrative
Income statement: notes and sources
Notes: FY2022 EPS of 32.7c is the restated fair value comparative shown in the FY2023 release, whereas FY2022 PBT of A$10.7m is the original historical-cost figure; the two are on different bases. FY2021 comparatives: revenue A$37.1m, PBT A$12.9m, gross profit A$26.6m. Discrepancy: one press report (QuotedData, October 2025) cited an FY25 post-tax loss of A$79m, but LCM's audited FY25 accounts and FY26 comparatives show A$72.913m; the audited figure is used here. EBITDA is not reported. Because LCM has negligible depreciation (A$0.07m in FY26), operating profit is a close proxy.
Margins (derived, LCM-only basis)
Margins are not meaningful in FY2025 and FY2026 because total income was negative. A revenue CAGR is not meaningful: income turned negative in FY2025.
Balance sheet
Borrowings have no short/long-term split because the balance sheet is presented in order of liquidity. The whole Northleaf facility was a single term facility; after the 30 September 2026 amendment it runs to 31 December 2030. There is no goodwill. Working capital is not presented. The FY2022 equity figure comes from a secondary data provider (Shares Magazine) and its basis (historical-cost versus restated) is unconfirmed.
Ratios (derived)
ROE and debt/equity are not meaningful for FY2026 because equity is negative. Net debt/EBITDA, current ratio, asset turnover, ROIC and cash conversion cycle are not meaningful for a litigation-asset balance sheet presented in liquidity order, and the company does not report them.
Commentary on trends, inflections and drivers
FY2022–FY2023: the scale-up. Assets under management grew from A$336m (FY21) to A$484m (FY23). The FY23 switch to fair value accounting brought forward recognition of unrealised gains. Fund I realisations produced FY23 realised income of A$181m (A$84m attributable to LCM), and LCM cash reached A$83m.
FY2024: the peak. The balance sheet peaked at A$188.9m of net assets. New commitments hit a record A$279m and the company returned A$10.4m via dividends and buybacks while committing heavily. This was the decisive inflection. Capital was being deployed and distributed just as concentration was rising, and a new debt facility followed in December 2024.
FY2025: the first loss year. LCM recorded 6 wins against 6 losses, plus 3 trial losses taken to appeal. Fair value movement swung A$112.6m (from +A$12.5m to -A$100.1m). Net debt rose from A$8.9m to A$68.9m as A$59.8m went into case funding while only A$33.6m came back. The going-concern material uncertainty first appeared here.
FY2026: collapse. Eight investments concluded, seven of them losses. Proceeds on LCM capital were just A$1.1m against A$38.0m of cost. Uninsured adverse costs (A$12.9m on Queensland Electricity), an adverse-costs provision (A$4.2m) and the Fund I clawback provision (A$20.4m) compounded the losses. Finance costs rose 72% to A$12.5m on higher drawings and a 200bp waiver margin. Cost cutting (operating expenses down 39%) was immaterial against portfolio losses.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products / services |
|---|---|---|
LCM | Parent and wholly owned subsidiaries: 100% balance-sheet investments, the 25% co-investment in Funds I and II, and corporate operations | Single-case funding, portfolio funding, claim acquisitions, fund management (performance fees) |
Fund (Fund I and Fund II) | LCM Global Alternative Returns Fund and Fund II, consolidated under AASB 10 because LCM controls them; holds the 75% third-party co-investment and fund administration costs | Third-party LP capital deployed alongside LCM |
Results by Segment and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
LCM segment total income (AUD Mn) | 44.718 | -82.028 | -152.076 |
Fund segment total income (AUD Mn) | 3.033 | 3.569 | -0.455 |
Consolidated total income (AUD Mn) | 47.752 | -78.459 | -152.531 |
LCM segment share of consolidated (%) | 93.6 | 104.5 | 99.7 |
Revenue by Segment
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
LCM net realised gain (AUD Mn) | 23.033 | 22.187 | -63.889 |
Fund net realised gain (AUD Mn) | 38.744 | 21.456 | -51.879 |
Consolidated net realised gain (AUD Mn) | 61.778 | 43.643 | -115.768 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment — LCM net unrealised movement
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
LCM net unrealised movement (AUD Mn) | 12.477 | -100.103 | -54.127 |
Fund net unrealised movement (AUD Mn) | 12.671 | -106.664 | -30.542 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross profit, historical-cost basis as originally reported, incl. third parties (AUD Mn) | 31.1 | — | — | — | — |
LCM-only total income / (loss) (AUD Mn) | — | 67.7 | 44.7 | -82.0 | -152.1 |
Consolidated total income / (loss) (AUD Mn) | — | — | 47.752 | -78.459 | -152.531 |
LCM-only net realised gain / (loss) (AUD Mn) | — | 51.5 | 23.0 | 22.2 | -63.9 |
LCM-only net fair value movement (AUD Mn) | — | — | 12.5 | -100.1 | -54.1 |
LCM-only operating expenses (AUD Mn) | — | — | 19.0 | 18.0 | 11.0 |
Consolidated operating profit / (loss) (AUD Mn) | — | — | 26.133 | -94.392 | -161.085 |
Finance costs, consolidated (AUD Mn) | — | — | 10.083 | 7.295 | 12.512 |
Profit / (loss) before tax (AUD Mn) | 10.7 | — | 16.050 | -101.687 | -173.597 |
Income tax (expense) / benefit (AUD Mn) | — | — | -3.335 | 28.774 | 7.861 |
Net profit / (loss) after tax (AUD Mn) | — | 31.5 | 12.715 | -72.913 | -165.736 |
Basic EPS (A cents) | 32.7 | 29.5 | 12.01 | -70.83 | -160.88 |
Diluted EPS (A cents) | — | — | 11.33 | -70.83 | -160.88 |
Dividend per share declared for the year (GBp) | — | 2.25 | 1.25 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2023 | FY2024 |
|---|---|---|
Operating margin on LCM total income (%) | — | 58.8 |
Pre-tax margin on LCM total income (%) | — | 35.9 |
Net margin on LCM total income (%) | 46.5 | 28.4 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets, consolidated (AUD Mn) | — | — | 591.803 | 445.558 | 274.845 |
Total assets, LCM-only (AUD Mn) | — | — | 314.4 | 214.0 | 107.3 |
Cash, consolidated (AUD Mn) | 50.0 | 104.5 | 68.113 | 18.447 | 10.415 |
Cash, LCM-only (AUD Mn) | 29.3 | 83.0 | 53.0 | 8.9 | 2.1 |
Borrowings, total (AUD Mn) | — | — | 61.917 | 77.747 | 125.512 |
Net debt, LCM-only (AUD Mn) | — | — | 8.9 | 68.9 | 123.4 |
Investments at fair value, LCM-only (AUD Mn) | — | — | 202.9 | 124.8 | 62.2 |
Investments at cost (AASB 15), LCM-only (AUD Mn) | — | — | 42.1 | 48.0 | 18.1 |
Third-party interests in consolidated funds (AUD Mn) | — | — | 264.950 | 226.538 | 177.147 |
Deferred tax liability (AUD Mn) | — | — | 43.624 | 15.286 | 7.425 |
Intangible assets (AUD Mn) | — | — | 0.305 | 0.439 | 0.380 |
Total equity / (deficit) (AUD Mn) | 148.93 | 183.469 | 188.941 | 114.370 | -53.646 |
NAV per share, basic (GBp) | — | 90.3 | 94.4 | 53.2 | — |
Cash Flow
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Net operating cash flow (AUD Mn) | 19.203 | -80.454 | -91.857 |
Proceeds from litigation contracts (AUD Mn) | 116.636 | 64.702 | 3.058 |
Payments for litigation contracts (AUD Mn) | 78.265 | 128.166 | 82.315 |
Capex, PP&E plus intangibles (AUD Mn) | 0.040 | 0.206 | 0 |
Free cash flow, derived OCF less capex (AUD Mn) | 19.163 | -80.660 | -91.857 |
Dividends paid (AUD Mn) | 4.976 | 2.680 | 0 |
Share buybacks / treasury shares (AUD Mn) | 5.396 | 5.318 | 0 |
Proceeds from borrowings (AUD Mn) | 0 | 25.039 | 43.087 |
Repayment of borrowings (AUD Mn) | 8.139 | 12.864 | 0 |
Dividends & Capital Returns
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Opening cash (AUD Mn) | 83.0 | 53.0 | 8.9 |
Cash from concluded investments (AUD Mn) | 56.7 | 33.6 | 2.4 |
Cash invested into ongoing cases (AUD Mn) | -39.7 | -59.8 | -37.7 |
Operating expenses paid (AUD Mn) | -17.0 | -16.0 | -11.1 |
Net finance costs paid (AUD Mn) | -9.0 | -6.5 | -3.5 |
Dividends and buybacks (AUD Mn) | -10.4 | -8.0 | 0.0 |
Net debt drawdown / (repayment) (AUD Mn) | -8.1 | 12.2 | 43.1 |
Closing cash (AUD Mn) | 53.0 | 8.9 | 2.1 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
ROE, PAT / average equity (%) | 6.8 | -48.1 | — |
ROA, PAT / year-end consolidated total assets (%) | 2.1 | -16.4 | -60.3 |
ROA, PAT / year-end LCM-only total assets (%) | 4.0 | -34.1 | -154.5 |
Debt / equity (x) | 0.33 | 0.68 | — |
Interest coverage, operating profit / finance costs (x) | 2.6 | -12.9 | -12.9 |
Net debt / LCM-only total assets (%) | 2.8 | 32.2 | 115.0 |
Region Assets & Liabilities and Revenue by Region (%)
| Metric | FY2025 | H1 FY2026 |
|---|---|---|
APAC Level 3 litigation funding assets (AUD Mn) | 81.220 | 87.831 |
EMEA Level 3 litigation funding assets (AUD Mn) | 206.515 | 115.898 |
Total Level 3 assets (AUD Mn) | 287.735 | 203.729 |
APAC share (%) | 28.2 | 43.1 |
Share Price History
| Date | Price (GBp) | Source / context |
|---|---|---|
Pre-1 Oct 2025 | 26.6 | Implied from the 16p fall to 10.6p |
1 Oct 2025 | 10.6 | After UK High Court loss (QuotedData) |
2 Apr 2026 | 3.8 | Fidelity bid price |
Oct 2026 | 1.53 | Stockopedia; market cap about £1.74m |
Valuation Multiples
| Multiple | LCM | Comment |
|---|---|---|
P/E | n/m | Loss-making. Stockopedia's displayed trailing P/E of 1.55 appears to be a data error and should be disregarded |
P/B | n/m | Negative book value |
EV/Sales, EV/EBITDA | n/m | Negative income |
Analyst consensus | Stockopedia shows a "Buy" consensus with a 104.15p target | Clearly stale (pre-collapse); treat as unreliable |
Dividends & Capital Returns (FY2023–FY2026)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Dividend declared per share (GBp) | 2.25 | 1.25 | 0 | 0 |
Dividends paid (AUD Mn) | — | 4.976 | 2.680 | 0 |
Buyback / treasury share purchases (AUD Mn) | — | 5.396 | 5.318 | 0 |
Capital Markets
| Item | Detail |
|---|---|
Facility | Northleaf senior secured term facility (Facility B of the Amended and Restated Senior Term Facility Agreement) |
Limit | US$125m (from US$100m), subject to conditions precedent |
Maturity | 31 December 2030 |
Pricing | SONIA + 1,000bp, fully PIK (previously 525bp plus 200bp during waivers) |
Repayment | Greater of (i) principal plus capitalised interest or (ii) 2x principal drawn |
Upside sharing | 25% of gross cash proceeds of remaining investments (including fund performance fees) if repaid before the portfolio concludes |
Recourse | Limited recourse to the case portfolio |
Covenants | New run-off covenants; first test 31 December 2027 |
Carrying amount | A$125.5m at 30 June 2026 |
Analyst Conclusions
Management guidance
No financial guidance is given. Management's plan is to manage the 37-case portfolio to conclusion under a business plan approved by Northleaf, cut costs further and apply all realisations to the facility. No sell-side consensus is credible or current.
Bull case
-
Appeal reversals. Four cases lost at first instance (A$66m invested) are carried at only A$33m. Successful appeals would lift asset values materially.
-
Large receivables crystallise. The Green-X v Poland awards survived a Singapore set-aside challenge, and LCM-only receivables are A$21.2m. Collection, plus trademark damages, would bring in cash at low cost.
-
Side recoveries. The Gladstone solicitor recovery, a possible Dubai compensation claim and A$62.3m of unrecognised tax losses offer non-portfolio upside.
Bear case
-
The lender's claim compounds faster than assets realise. At FY26, LCM-only total assets were A$107.3m against total liabilities of A$160.9m. PIK interest at SONIA + 10% and the 2x-principal floor make the hurdle before any equity value very high.
-
The loss rate has not normalised. Seven of eight FY26 conclusions were losses, and further losses followed after year-end (July and October 2026).
-
Contingent liabilities are larger than provided for. These include clawback (A$20.4m provided), under-insured adverse costs (A$4.2m provided against a A$4–8m contingent range) and going-concern conditions precedent.
Catalysts and monitorables (next 12 months)
-
Satisfaction of the remaining conditions precedent to the Northleaf amendment.
-
Appointment of the two Northleaf-nominated directors at LCM Group Holdings.
-
Appeal outcomes on the four cases lost at first instance.
-
Collection progress on the Poland awards and any further set-aside rulings.
-
Damages quantification in the trademark case.
-
FY26 annual report, AGM (late November 2026) and any resolutions on the company's listing status.
-
H1 FY27 results (about March 2027): cash realised versus PIK accrual.
-
Final crystallisation of the Fund I clawback.
-
Further adverse-costs awards.
Analyst verdict
Litigation Capital Management is no longer an operating litigation financier in any forward-looking sense. It is a lender-controlled liquidation of a damaged portfolio. The numbers leave little room for interpretation. Two consecutive years of losses (A$72.9m and A$165.7m) consumed the entire equity base and left net liabilities of A$53.6m. Cash generation from concluded investments fell to A$2.4m in FY26 while A$37.7m was still being deployed. The strategic review, despite talks with "credible counterparties", produced no transaction. The board has instead accepted Northleaf terms that are punitive by design: fully PIK interest at SONIA plus 1,000bp, repayment of at least twice drawn principal, 25% of residual proceeds after repayment, limited recourse, and lender-nominated directors at the operating subsidiary.
The causes are clear from LCM's own admissions: concentration in a handful of large class actions and commercial claims, escalating commitments to failing cases, weak scrutiny of expert evidence, and leverage added near the top of the cycle. Fair value accounting magnified the optics on the way up and reversed sharply on the way down. In FY25, cases held at 2.8x cost before conclusion realised 1.8x.
For shareholders, the relevant question is no longer earnings or valuation multiples. It is whether portfolio realisations can exceed the lender's compounding claim by a wide enough margin to leave any residual. On current disclosures that looks remote. Appeal reversals and the Polish awards provide genuine but limited optionality. The roughly £1.7m market capitalisation prices this as a deep out-of-the-money call. For creditors and fund LPs the story is recovery management. For the sector, LCM is a case study in the risks of combining single-case binary exposure, small scale and senior debt.
Verdict: Equity is speculative and effectively subordinated to the lender. The dossier assigns no fundamental value to the shares beyond option value, and rates the business as being in terminal run-off.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Tenure / background (as disclosed) | Shareholding (Simply Wall St, c. June 2025) |
|---|---|---|---|
Jonathan Moulds | Non-Executive Chairman | Chair through the AIM era; signs the FY25 Chairman's statement and interim reports. Prior roles and education not disclosed in sources reviewed | 5,250,000 (5.04%) |
Patrick Moloney | Chief Executive Officer, Executive Director | Long-standing CEO; built the track record from the predecessor business; led the AIM listing, fund strategy and run-off | 11,870,122 (11.4%) |
Dr David King | Non-Executive Director | Details not disclosed in sources reviewed | 1,951,484 (1.87%) |
David Collins | Chief Financial Officer, Executive Director | CFO with "more than 12 months in the role" by October 2025; appointed to the Board 6 December 2024; led the fair value model review | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change |
|---|---|
6 Dec 2024 | CFO David Collins joins the Board |
FY2025 | Gerhard Seebacher steps down as Non-Executive Director after more than four years |
| 2025 | Two of three former senior NEDs gone; the Board shrinks to 2 non-executives and 2 executives |
30 Sep 2026 (pending) | Two Northleaf-nominated independent directors to join the board of subsidiary LCM Group Holdings Pty Ltd, through which all investments are held |
Directors' Remuneration
| Metric | FY2025 | FY2026 |
|---|---|---|
Salaries and wages (AUD K) | 8,431 | 5,191 |
Severance payments (AUD K) | 591 | 617 |
Non-executive directors' fees (AUD K) | 420 | 349 |
Share-based payments expense (AUD K) | 1,117 | 563 |
Major Shareholders
| Holder | Shares | Stake (%) |
|---|---|---|
Collins St Asset Management Pty Ltd | 14,869,816 | 14.3 |
Patrick Moloney | 11,870,122 | 11.4 |
Jonathan Moulds | 5,250,000 | 5.04 |
Tectonic Investment Management Pty Ltd | 4,908,659 | 4.71 |
Pendal Group (Perpetual) | 3,489,688 | 3.35 |
David King | 1,951,484 | 1.87 |
Aberdeen Group plc | 1,859,202 | 1.79 |
Michael Barben | 913,239 | 0.88 |
BN & Partners Capital AG | 224,962 | 0.22 |
Mary Gangemi | 64,348 | 0.06 |
Competitive Landscape
Key Competitors
| Competitor | Listing / type | Overlap with LCM | Relative positioning |
|---|---|---|---|
Burford Capital | NYSE / LSE (BUR) | Global commercial, treaty and corporate portfolio funding | Market leader by scale; YPF exposure; appeal decision announced March 2026 |
Omni Bridgeway | ASX (OBL) | Australian class actions, insolvency, global commercial | Direct Australian rival; FY26 statutory NPAT A$45.9m; debt-free; AuM over A$5.9bn |
Manolete Partners | AIM (MANO) | UK insolvency claims acquisition | Overlaps the "acquisition of claims" strategy |
Harbour Litigation Funding | Private (UK) | UK commercial and group actions | Larger UK specialist |
Therium Capital | Private (UK) | UK and international commercial | Peer; LCM's CEO notes several peers have ceased operations |
Woodsford | Private (UK) | UK collective (competition) actions | Competition-claim rival |
Bench Walk Advisors | Private (US/UK) | Commercial and arbitration | Fund-model peer |
Fortress Investment Group (legal assets) | Private | Large-ticket legal assets | Deep-pocketed capital provider |
Longford Capital | Private (US) | US commercial / IP | Relevant to LCM's abortive US plans |
Deminor | Private (EU) | Arbitration and enforcement | EMEA competitor |
CASL / Australian class action funders | Private (AU) | Australian class actions | Domestic competition |
Peer Comparison FY2026
| Metric | LCM (FY26, A$) | Omni Bridgeway (FY26, A$) | Burford (FY24, US$) |
|---|---|---|---|
Net profit / (loss) (m) | -165.7 | 45.9 | 146.5 |
Total income / revenue (m) | -152.1 | — | 472.3 |
AuM / FuM | US$339m FuM (FY25) | over A$5.9bn | — |
Balance-sheet debt | A$125.5m | Debt-free | — |
R&D intensity (%) | 0 | — | — |
Recent Developments
--



